Rilzabrutinib shows promise for immune thrombocytopenia in phase 1-2 trial: NEJM Dr. Kamal Kant Kohli18 April 2022 10:15 AM ISTBOSTON: In people with immune thrombocytopenia (ITP), the body produces destructive antibodies against platelets in the blood, which increases the...
Carbonic anhydrase inhibitor, sulthiame new potential treatment of sleep apnea Dr. Kamal Kant Kohli15 April 2022 7:15 PM ISTSeveral drugs with carbonic anhydrase (CA) inhibitory properties are already available on the market, and used for treatment of glaucoma, epilepsy and...
Drug use severity in adolescence tied to substance use disorder risk in adulthood: JAMA Dr. Kamal Kant Kohli5 April 2022 9:00 AM ISTPeople who reported multiple symptoms consistent with severe substance use disorder at age 18 exhibited two or more of these symptoms in adulthood,...
Reduced kidney function increases bleeding risk in antithrombotic therapy Dr. Kamal Kant Kohli29 March 2022 9:00 AM ISTAntithrombotic therapy is prescribed to prevent thrombotic (blood clotting inside a blood vessel) events but the treatment also increases the...
